Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 9, Pages 1231-1238
Publisher
American Society of Clinical Oncology (ASCO)
Online
2013-01-29
DOI
10.1200/jco.2012.44.0958
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924
- (2012) Michael A. Milhollen et al. CANCER CELL
- A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair
- (2012) Ko Sato et al. CURRENT BIOLOGY
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
- (2012) Dennis L. Buckley et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The Ubiquitin-Proteasome System Meets Angiogenesis
- (2012) N. Rahimi MOLECULAR CANCER THERAPEUTICS
- Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma
- (2012) Luca Busino et al. NATURE CELL BIOLOGY
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- (2012) Christopher E Barbieri et al. NATURE GENETICS
- MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate Cancer
- (2012) Barbara Benassi et al. Cancer Discovery
- The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer
- (2012) Qing Zhang et al. Frontiers in Oncology
- Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity
- (2011) Vaibhav Kapuria et al. BIOCHEMICAL PHARMACOLOGY
- Role of the ubiquitin ligase Fbw7 in cancer progression
- (2011) Yabin Cheng et al. CANCER AND METASTASIS REVIEWS
- Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13
- (2011) Junli Liu et al. CELL
- Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer
- (2011) Meng Wang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- p53 regulation by ubiquitin
- (2011) Christopher L. Brooks et al. FEBS LETTERS
- Polyubiquitin Linkage Profiles in Three Models of Proteolytic Stress Suggest the Etiology of Alzheimer Disease
- (2011) Eric B. Dammer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Systematic and Quantitative Assessment of the Ubiquitin-Modified Proteome
- (2011) Woong Kim et al. MOLECULAR CELL
- UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53
- (2011) Hong Wu et al. NATURE MEDICINE
- Deubiquitinases in cancer: new functions and therapeutic options
- (2011) J M Fraile et al. ONCOGENE
- Role of Pirh2 in Mediating the Regulation of p53 and c-Myc
- (2011) Anne Hakem et al. PLoS Genetics
- MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma
- (2010) M. A. Milhollen et al. BLOOD
- The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma
- (2010) G. W. Xu et al. BLOOD
- Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
- (2010) R. T. Swords et al. BLOOD
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells
- (2010) Shinji Endo et al. CANCER SCIENCE
- Will the Ubiquitin System Furnish as Many Drug Targets as Protein Kinases?
- (2010) Philip Cohen et al. CELL
- Unlocking the Mdm2-p53 loop: Ubiquitin is the key
- (2010) Hilary V. Clegg et al. CELL CYCLE
- Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
- (2010) G. Zauli et al. CLINICAL CANCER RESEARCH
- Suppressor of fused and Spop regulate the stability, processing and function of Gli2 and Gli3 full-length activators but not their repressors
- (2010) C. Wang et al. DEVELOPMENT
- Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways
- (2010) Tongsen Zheng et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
- (2010) James E. Brownell et al. MOLECULAR CELL
- An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase
- (2010) Stephen Orlicky et al. NATURE BIOTECHNOLOGY
- Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase
- (2010) Mariam Aghajan et al. NATURE BIOTECHNOLOGY
- Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
- (2010) Lynn Bedford et al. NATURE REVIEWS DRUG DISCOVERY
- p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma
- (2010) Jong-Lyel Roh et al. ORAL ONCOLOGY
- Targeting p53 for enhanced radio- and chemo-sensitivity
- (2009) Chao Lu et al. APOPTOSIS
- Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1α
- (2009) Yoon-Mi Lee et al. CARCINOGENESIS
- The multiple levels of regulation by p53 ubiquitination
- (2009) J T Lee et al. CELL DEATH AND DIFFERENTIATION
- Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer
- (2009) T. A. Soucy et al. CLINICAL CANCER RESEARCH
- Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047)
- (2009) Han-Jie Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells
- (2009) F. Colland et al. MOLECULAR CANCER THERAPEUTICS
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways
- (2009) Brenda A. Schulman et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Analysis of Drosophila Segmentation Network Identifies a JNK Pathway Factor Overexpressed in Kidney Cancer
- (2009) J. Liu et al. SCIENCE
- Atypical ubiquitin chains: new molecular signals. ‘Protein Modifications: Beyond the Usual Suspects’ Review Series
- (2008) Fumiyo Ikeda et al. EMBO REPORTS
- Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
- (2008) Sharmila Patel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The potential of proteasome inhibitors in cancer therapy
- (2008) Jan Sterz et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
- (2008) Sanjeev Shangary et al. MOLECULAR CANCER THERAPEUTICS
- The genetics of the p53 pathway, apoptosis and cancer therapy
- (2008) Alexei Vazquez et al. NATURE REVIEWS DRUG DISCOVERY
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
- (2008) S. Shangary et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression
- (2008) Jian-Hua Mao et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started